A Phase I, Parallel-group, Multi-center, Open-label, Investigation of the Pharmacokinetics, Safety and Tolerability of a Single Subcutaneous Injection of Cotadutide in Participants With Mild, Moderate or Severe Hepatic Impairment Compared to Participants With Normal Hepatic Function
Latest Information Update: 27 Mar 2023
At a glance
- Drugs Cotadutide (Primary)
- Indications Non-alcoholic fatty liver disease; Non-alcoholic steatohepatitis; Obesity; Type 2 diabetes mellitus
- Focus Pharmacokinetics
- Sponsors AstraZeneca
- 17 Mar 2023 Status changed from recruiting to discontinued. Discontinuing the development of cotadutide, a daily injectable GLP-1/glucagon co-agonist, is based on strategic pipeline considerations.The premature closure is not due to any newly observed safety signals or a change in therisk/benefit profile.
- 17 Feb 2023 Planned End Date changed from 29 Mar 2023 to 26 Jun 2023.
- 17 Feb 2023 Planned primary completion date changed from 29 Mar 2023 to 26 Jun 2023.